- Home
- TBBK vs CNTA Comparison
TBBK vs CNTA Comparison
Compare TBBK & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBBK
- CNTA
- Stock Information
- Founded
- TBBK 1999
- CNTA 2020
- Country
- TBBK United States
- CNTA United Kingdom
- Employees
- TBBK N/A
- CNTA N/A
- Industry
- TBBK Major Banks
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- TBBK Finance
- CNTA Health Care
- Exchange
- TBBK Nasdaq
- CNTA Nasdaq
- Market Cap
- TBBK 2.9B
- CNTA 2.3B
- IPO Year
- TBBK 2004
- CNTA 2021
- Fundamental
- Price
- TBBK $72.73
- CNTA $17.01
- Analyst Decision
- TBBK Buy
- CNTA Strong Buy
- Analyst Count
- TBBK 4
- CNTA 10
- Target Price
- TBBK $68.00
- CNTA $30.56
- AVG Volume (30 Days)
- TBBK 670.6K
- CNTA 1.2M
- Earning Date
- TBBK 07-24-2025
- CNTA 08-12-2025
- Dividend Yield
- TBBK N/A
- CNTA N/A
- EPS Growth
- TBBK 21.62
- CNTA N/A
- EPS
- TBBK 4.65
- CNTA N/A
- Revenue
- TBBK $515,889,000.00
- CNTA $15,000,000.00
- Revenue This Year
- TBBK N/A
- CNTA N/A
- Revenue Next Year
- TBBK $23.36
- CNTA N/A
- P/E Ratio
- TBBK $14.53
- CNTA N/A
- Revenue Growth
- TBBK 11.18
- CNTA 118.88
- 52 Week Low
- TBBK $40.51
- CNTA $9.60
- 52 Week High
- TBBK $72.77
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- TBBK 71.21
- CNTA 54.91
- Support Level
- TBBK $65.05
- CNTA $17.01
- Resistance Level
- TBBK $68.49
- CNTA $18.14
- Average True Range (ATR)
- TBBK 2.09
- CNTA 0.81
- MACD
- TBBK 0.33
- CNTA -0.10
- Stochastic Oscillator
- TBBK 98.72
- CNTA 51.08
About TBBK The Bancorp Inc
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, specialty finance (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Specialty finance includes REBL (real estate bridge lending) comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.